Johnson & Johnson (NYSE:JNJ) will unveil its latest earnings on Tuesday, April 17, 2012. The average analyst estimate is for net income of $1.36 per share, a rise of 0.7% from the company’s actual earnings for the year-ago quarter. During the past three months, the average estimate has moved up from $1.33. Between one and three months ago, the average estimate moved up. It has risen from $1.35 during the last month. Analysts are projecting profit to rise by 2% compared to last year’s $5.10.

Last quarter, the company beat estimates by 3 cents, coming in at profit of $1.13 a share versus the estimate of net income of $1.10 a share. It marked the fourth straight quarter of beating estimates. On average, analysts predict $16.27 billion in revenue this quarter, a rise of 0.6% from the year-ago quarter. Analysts are forecasting total revenue of $66.4 billion for the year, a rise of 2.1% from last year’s revenue of $65.03 billion.

Forest Laboratories, Inc. (NYSE:FRX) will unveil its latest earnings on Tuesday, April 17, 2012. The average analyst estimate is for profit of 70 cents per share, a decline of 37.5% from the company’s actual earnings for the year-ago quarter. During the past three months, the average estimate has moved up from 69 cents. Between one and three months ago, the average estimate moved up. It has been unchanged at 70 cents during the last month. Analysts are projecting profit to rise by 16.1% compared to last year’s $3.70.

The company topped estimates last quarter after missing forecasts the quarter prior. In the third quarter, it reported net income of $1.04 per share against a mean estimate of profit of $1 per share. In the second quarter, it missed forecasts by 8 cents. On average, analysts predict $1.02 billion in revenue this quarter, a decline of 10.5% from the year-ago quarter. Analysts are forecasting total revenue of $4.53 billion for the year, a rise of 2.5% from last year’s revenue of $4.42 billion.

Intuitive Surgical, Inc. (NASDAQ:ISRG) will unveil its latest earnings on Tuesday, April 17, 2012. The average estimate of analysts is for net income of $3.14 per share, a rise of 21.2% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from $3.16. Between one and three months ago, the average estimate moved up. It has dropped from $3.17 during the last month. For the year, analysts are projecting profit of $14.53 per share, a rise of 17.9% from last year.

The company has beaten estimates the last four quarters and is coming off a quarter where it topped forecasts by 41 cents, reporting net income of $3.75 per share against a mean estimate of profit of $3.34 per share. Analysts are projecting a rise of 19.5% in revenue from the year-earlier quarter to $463.8 million.

Abbott Laboratories (NYSE:ABT) will unveil its latest earnings on Wednesday, April 18, 2012. The average analyst estimate is for net income of 99 cents per share, a rise of 8.8% from the company’s actual earnings for the year-ago quarter. During the past three months, the average estimate has moved down from $1.04. Between one and three months ago, the average estimate moved down. It has been unchanged at 99 cents during the last month. Analysts are projecting profit to rise by 7.7% compared to last year’s $5.03.

Last quarter, the company beat estimates by one cent, coming in at profit of $1.45 a share versus the estimate of net income of $1.44 a share. It marked the fourth straight quarter of beating estimates. Analysts predict a rise of 3.4% in revenue from the year-earlier quarter to $9.35 billion.